In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US RNA company Avidity Biosciences closed 55% higher following Wednesday’s trading. 15 December 2022
Biotechnology
Adding to a string of approved indications for the interleukin (IL) and IL-4 blocking antibody, the European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. 15 December 2022
Biotechnology
A Danish company developing a vaccine against group B streptococcus (GBS) - an infection often known as Strep B - has 72 million ($77 million) euros more to spend. 15 December 2022
Pharmaceutical
Nucleic acid therapy specialist Exicure has been dealt a blow by the termination of collaborations with AbbVie and Ipsen. 15 December 2022
Pharmaceutical
A novel targeted protein degradation (TPD) candidate from Kymera Therapeutics is to be advanced by its research and development partner, Sanofi. 15 December 2022
Pharmaceutical
US eyecare pharma company Harrow Health’s shares jumped 15% to $12.77 after it announced a binding agreement for the acquisition of the exclusive US commercial rights to five Food and Drug Administration (FDA) approved ophthalmic products from Swiss pharma giant Novartis 15 December 2022
Pharmaceutical
Prices for a wide range of drugs in the Russian pharmaceutical retail sector are steadily growing due to a significant reduction of their supplies and disappearance from retail shelves. 15 December 2022
Generics
The Russian government together with some leading domestic financial corporations will provide support to domestic producers of active pharmaceutical ingredients (APIs) that will primarily be in the form of provision of preferential loans and other benefits for them, reports The Pharma Letter’s local correspondent. 15 December 2022
Biotechnology
As the year draws to a close, this article presents some of the wins of the orphan drug community in terms of US FDA approvals, while highlighting challenges faced by the sector and looking ahead to the expectations of the next year. 15 December 2022
Pharmaceutical
India’s Torrent Pharmaceuticals has inked a strategic alliance with Germany’s Boehringer Ingelheim to co-market diabetes drugs and fixed-dose combinations in India. The Indian company will co-market empagliflozin, empagliflozin+ metformin and empagliflozin+ linagliptin in India. 15 December 2022
Biotechnology
As anticipated, following a positive decision from its scientific committee, the European Medicines Agency has granted marketing authorization for Pluvicto (vipivotide tetraxetan). 14 December 2022
Biotechnology
Sanofi and Regeneron’s interleukin (IL)-13 and IL-4 blocking antibody Dupixent (dupilumab) is already an enormously successful drug, even though safety issues have been identified. 14 December 2022
Biotechnology
Replay, a genome writing company reprogramming biology by writing and delivering big DNA, has announced the launch of Kaleibe, a herpes simplex virus (HSV) gene therapy company targeting genetic brain disorders. 14 December 2022
Pharmaceutical
UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending Ofev (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF) in adults with a forced vital capacity (FVC) above 80% predicted. 14 December 2022
Pharmaceutical
As the 64th annual meeting of the American Society of Hematology (ASH) drew to a close in New Orleans on Tuesday, more clinical updates provided a window into the development prospects for two important programs in this therapy area. 14 December 2022
Biotechnology
French drug resistance specialist Ribonexus has appointed Steven Powell as chief executive, as the company prepares to seek more financing for its small molecule programs. 14 December 2022
Pharmaceutical
The US Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted eight to three that the benefits of omecamtiv mecarbil do not outweigh its risks for the treatment of heart failure with reduced ejection fraction (HFrEF). 14 December 2022
Pharmaceutical
Eli Lilly saw its shares close down 2.3% at $358.66, after the US major announced financial guidance for 2023, which was viewed as slightly disappointing. 14 December 2022
Biotechnology
US clinical stage biotech Praxis Precision Medicines’ shares closed up nearly 5% yesterday and rose a further 2.3% to $2.25 pre-market, on the news of a strategic collaboration with Belgium’s UCB, based on Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies. 14 December 2022
Pharmaceutical
USA-based drug developers Tellus Therapeutics, a neonatal care company developing treatments for new-borns in the neonatal intensive care unit (NICU), and Peroxitech, emerging biopharma developing a novel peptide for treating acute lung injury (ALI), have announced the closing of Series A financings led by the Perceptive Xontogeny Venture Fund. 14 December 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze